82.00
+2.49(+3.13%)
Currency In USD
| Previous Close | 79.51 |
| Open | 79.42 |
| Day High | 82.6 |
| Day Low | 79.12 |
| 52-Week High | 99.5 |
| 52-Week Low | 54.1 |
| Volume | 494,133 |
| Average Volume | 475,736 |
| Market Cap | 1.84B |
| PE | 51.25 |
| EPS | 1.6 |
| Moving Average 50 Days | 81.82 |
| Moving Average 200 Days | 78.68 |
| Change | 2.49 |
If you invested $1000 in ANI Pharmaceuticals, Inc. (ANIP) since IPO date, it would be worth $2,468.39 as of January 30, 2026 at a share price of $82. Whereas If you bought $1000 worth of ANI Pharmaceuticals, Inc. (ANIP) shares 4 years ago, it would be worth $2,736.98 as of January 30, 2026 at a share price of $82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 11:50 AM GMT
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Dise
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
GlobeNewswire Inc.
Dec 02, 2025 11:50 AM GMT
Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise for a meaningful impact on patientsPRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or